Homepage

Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries

Screening Compounds Building blocks

Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls

Company News & Media Contact us For suppliers Trends in discovery compounds

Homepage > Company > Media > Pharma News > 2025 > Gene therapy maker Sarepta tells FDA it won't halt shipments despite patient deaths

Gene therapy maker Sarepta tells FDA it won't halt shipments despite patient deaths

Gene therapy maker Sarepta tells FDA it won't halt shipments despite patient deaths

Read also

Senhwa Biosciences CX-5461

Senhwa Biosciences CX-5461

Senhwa Biosciences CX-5461 Secures NCI Support to Advance into MYC-Driven Lymphoma, Driving Cross-Cancer and Global Licensing Value

FDA Grants Breakthrough Therapy Designation to Olomorasib

FDA Grants Breakthrough Therapy Designation to Olomorasib

FDA Grants Breakthrough Therapy Designation to Olomorasib With Pembrolizumab for NSCLC

Clene Inc

Clene Inc. announces preclinical data showing CNM-Au8 enhances cellular health in Parkinson’s disease models, supporting further clinical development

Gelteq

Gelteq Announces Commencement of Preclinical Trial for Novel Gel-Based Antihistamine Formulation Targeting Allergy Market